SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
zch
Lv1
20 积分
2022-11-11 加入
最近求助
最近应助
互助留言
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
11天前
已完结
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
11天前
已完结
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
23天前
已完结
Global immunoglobulin supply: steaming towards the iceberg?
3个月前
已完结
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
5个月前
已完结
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
7个月前
已完结
[Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022)]
7个月前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
8个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
8个月前
已完结
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
8个月前
已完结
没有进行任何应助
感谢
11个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论